中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1360 records (took 0.034 seconds)

    Polymeric stents and method of manufacturing same
    164.
    发明授权
    Polymeric stents and method of manufacturing same 有权
    聚合物支架及其制造方法

    公开(公告)号：US09211204B2

    公开(公告)日：2015-12-15

    申请号：US13951139

    申请日：2013-07-25

    Applicant: Abbott Cardiovascular Systems Inc.

    Inventor： Brenna Hearn Lord

    IPC: G06G7/48 ,  A61F2/89 ,  A61F2/82 ,  B23K26/38 ,  B23K26/40

    CPC classification number: A61F2/89 ,  A61F2/82 ,  A61F2240/00 ,  B23K26/38 ,  B23K2101/06 ,  B23K2103/00 ,  B23K2103/42 ,  B23K2103/50 ,  Y10T29/49826

    Abstract: A pattern is used to form a stent scaffold from a polymeric precursor tube having a particular outer diameter. A new pattern can be derived from a base pattern, wherein the new pattern can be used to form a stent scaffold from a precursor tube having an outer diameter ODPR smaller than that needed for the base pattern. The new pattern can be derived by determining the shape of a stent scaffold, having the base pattern, after having been radially compressed to ODPR. The radially compressed shape is used to design the new pattern, which is applied to a precursor tube having an outer diameter ODPR. The new pattern can have a plurality of W-shaped closed cells, each W-shape closed cell bounded by struts oriented in such a way to form interior angles from about 80 degrees to about 95 degrees between every two adjacent struts.

    Abstract translation: 使用图案从具有特定外径的聚合物前体管形成支架支架。 可以从基本图案导出新的图案，其中可以使用新图案从具有小于基底图案所需的外径ODPR的前体管形成支架支架。 可以通过在经径向压缩至ODPR之后确定具有基本图案的支架支架的形状来获得新图案。 径向压缩形状用于设计新的图案，其应用于具有外径ODPR的前体管。 新图案可以具有多个W形封闭单元，每个W形闭合单元以由支柱定向的方式定向，以形成每两个相邻支柱之间的约80度至约95度的内角。

    Medical device fabrication process including strain induced crystallization with enhanced crystallization
    165.
    发明授权
    Medical device fabrication process including strain induced crystallization with enhanced crystallization 有权
    医疗器械制造工艺包括应变诱导结晶，增强结晶

    公开(公告)号：US09205575B2

    公开(公告)日：2015-12-08

    申请号：US14279215

    申请日：2014-05-15

    Applicant: Abbott Cardiovascular Systems Inc.

    Inventor： Lothar W. Kleiner ,  Fuh-Wei Tang

    IPC: B29C49/00 ,  B29C35/02 ,  B29C35/16 ,  B29C71/02 ,  B29C45/00 ,  B29C47/00 ,  B29L31/00

    CPC classification number: B29C35/16 ,  B29C45/0055 ,  B29C47/0038 ,  B29C71/02 ,  B29L2031/7534

    Abstract: Methods of fabricating a polymeric implantable device, such as a stent, with improved fracture toughness through annealing a polymer construct below the glass transition temperature of the polymer of the construct prior to a deformation step are disclosed herein. The deformation of the construct induces crystallization in the polymer construct through strain-induced crystallization. The annealing of the polymer construct accelerates the crystallization induced during the deformation and results in an increase in crystallite density with smaller crystallites as compared to deformation of a tube that has not been annealed. A stent scaffolding is then made from the deformed tube.

    Abstract translation: 本文公开了通过在变形步骤之前将构建体的聚合物的玻璃化转变温度退火到低于聚合物的玻璃化转变温度来制备具有改进的断裂韧性的聚合物可植入装置（例如支架）的方法。 构建体的变形通过应变诱导结晶在聚合物构造体中诱导结晶。 聚合物构件的退火加速了在变形期间引起的结晶，并且与没有退火的管的变形相比，结晶晶体密度随着较小晶粒的增加而增加。 然后从变形管制成支架式支架。

    Method of treating malignant solid tumors
    167.
    发明授权
    Method of treating malignant solid tumors 有权
    治疗恶性实体瘤的方法

    公开(公告)号：US09186329B2

    公开(公告)日：2015-11-17

    申请号：US13749612

    申请日：2013-01-24

    Applicant: Abbott Cardiovascular Systems Inc.

    Inventor： Paul M. Consigny

    IPC: A61K9/14 ,  A61K9/127 ,  A61K9/16 ,  A61K31/335

    CPC classification number: A61K9/146 ,  A61K9/127 ,  A61K9/1273 ,  A61K9/14 ,  A61K9/1629 ,  A61K31/335

    Abstract: This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of a drug capable of inhibiting mTOR and/or inhibiting an efflux pump and/or inhibiting HIF-1α and VEGF, the drug in particular being selected from the group consisting of sirolimus, everolimus, zotarolimus, tacrolimus, iolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, novolimus, 40-O-(3-hydroxypropyl), 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-tetrazolylrapamycin, the drug being administered along with a chemotherapeutic agent and/or radiation therapy.

    Abstract translation: 本发明涉及通过施用能够抑制mTOR和/或抑制外排泵和/或抑制HIF-1α和VEGF的药物来治疗实体瘤癌症，特别是难治性癌症的方法，该药物特别是选自组 由西罗莫司，依维莫司，佐他莫司，他克莫司，依维莫司A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司，诺罗维司40-O-（3-羟丙基），40-O- [2-（2-羟基）乙氧基] 雷帕霉素和40-O-四唑基雷帕霉素，该药物与化学治疗剂和/或放射治疗一起施用。

Patent Agency Ranking